Blog
34 Articles

Shedding More Light On Neoadjuvant Treatment
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.

Access and Disparities in Pancreatic Cancer Surgery Remain Pervasive Problems
Dr. Susan Tsai discusses her research into the causes of pancreatic cancer surgery and treatment disparities for underserved communities.

New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.

New Data Support Preoperative Chemoradiation Regimen for Borderline Resectable Pancreatic Cancer
Should patients get chemotherapy or chemoradiation before surgery? Dr. Matthew Katz provides an update on the Alliance study.

Adaptive Pre-Surgery Therapy for Patients with Localized Pancreatic Cancer
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?

The Pancreatic Standard of Care is No Longer So Standard
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.

Comparing Effectiveness of Chemotherapy Before and After Surgery
Is chemotherapy before and after pancreatic cancer surgery more effective than just chemotherapy after surgery?

Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.

Testing Techniques to Remove Stray Pancreatic Cancer Cells After Surgery
Researchers are studying whether peritoneal washing after pancreatic cancer surgery decreases recurrence of the cancer by removing stray cancer cells.